Injectable vaccine composition
US9962439B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 2, 2014 |
| Grant date | May 8, 2018 |
| Priority date | — |
| Expiry date | Oct 2, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55572
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention aims at providing an injectable vaccine composition that is safe, useful as a prophylactic or therapeutic agent for cancers or infectious diseases, and capable of inducing the systemic immune response safely and effectively. The present invention is an injectable vaccine composition to be administered by injection to a human being or an animal, containing: at least one antigen, and as an adjuvant, a lipopolysaccharide derived from at least one gram negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.